Effect of a δ Receptor Agonist on Duration of Survival during Hemorrhagic Shock

Objectives: Selective d receptor agonists have been shown to stabilize membrane physiologic processes, reduce metabolic rates, and provide protection against ischemic insults through KATP channel opening in a variety of organ beds. However, their potential for affecting outcomes in states of generalized ischemia has not been explored. The authors examined the effect of the nonselective d receptor agonist, DADLE (D-Ala2-Leu5-enkephalin), on hemodynamic stability and duration of survival in an animal model of severe hemorrhagic shock. Methods: Conscious Sprague Dawley rats with indwelling catheters were hemorrhaged at a rate of 3.25 mL/100 grams over 20 minutes after half of the group received 1% DADLE (1 mg/kg IV). Following the hemorrhage, all rats were continuously monitored for heart rate (HR), mean arterial pressure (MAP), and life signs for up to three hours (death defined as apnea, systolic blood pressure \ 30 mm Hg without pulsations, and electroencephalographic silence). Survival rates and hemodynamic trends were compared between the control and DADLE-treated groups. Results: In the 14 rats studied (8 DADLE; 6 controls), initial hemorrhage resulted in similar hemodynamic shock (average MAP fall: 118 to 59 vs 119 to 55 mm Hg). Analysis of survival at 3.5 hours revealed statistically significant differences between the control and DADLE groups. While 50% of the DADLE group survived past the three hours, no control animals were still alive at the end of the experimental period. The MAP trended downward and the HR increased for the control group, but all hemodynamic parameters stabilized in the rats treated with DADLE. Conclusions: Most current strategies for treating shock focus on the supply side of resuscitation. The coordinated various actions of DADLE have the potential to work in concert in the intact organism to improve overall survival during severe hemorrhagic shock. In an animal model of severe hemorrhagic shock, there was improvement in hemodynamic stability and a prolonged survival with DADLE treatment. Physiologic manipulation with DADLE appears to be a way to improve survival during shock with possible clinical implications. Key words: hemorrhagic shock; survival; DADLE. ACADEMIC EMERGENCY MEDICINE 2003; 10:587‐593. Selective d receptor agonists have been shown to reduce metabolic rates and provide protection against ischemic insults through kidney adenosine triphosphate (KATP) channel opening in a variety of organ

[1]  R. Carraway,et al.  Delta opiates increase ischemic tolerance in isolated rabbit jejunum. , 2002, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[2]  P. Molina.  Stress‐Specific Opioid Modulation Of Haemodynamic Counter‐Regulation , 2002, Clinical and experimental pharmacology & physiology.

[3]  P. Safar,et al.  Extending the golden hour of hemorrhagic shock tolerance with oxygen plus hypothermia in awake rats. An exploratory study. , 2002, Resuscitation.

[4]  Teruo Hayashi,et al.  Antiapoptotic and cytotoxic properties of delta opioid peptide [D‐Ala2,D‐Leu5]enkephalin in PC12 cells , 2002, Synapse.

[5]  C. Cairns.  Rude unhinging of the machinery of life: metabolic approaches to hemorrhagic shock , 2001, Current opinion in critical care.

[6]  R. Fryer,et al.  Dependence of delta1-opioid receptor-induced cardioprotection on a tyrosine kinase-dependent but not a Src-dependent pathway. , 2001, The Journal of pharmacology and experimental therapeutics.

[7]  D. Sigg,et al.  Opioid preconditioning: myocardial function and energy metabolism. , 2001, The Annals of thoracic surgery.

[8]  S. Bolling,et al.  Myocardial protection by ischemic preconditioning and delta-opioid receptor activation in the isolated working rat heart. , 2001, The Journal of thoracic and cardiovascular surgery.

[9]  L. Tsao,et al.  Hibernation-induction peptide and cell death: [D-Ala2,D-Leu5]enkephalin blocks Bax-related apoptotic processes. , 2001, European journal of pharmacology.

[10]  W. Millington,et al.  Blockade of delta opioid receptors in the ventrolateral periaqueductal gray region inhibits the fall in arterial pressure evoked by hemorrhage. , 2001, The Journal of pharmacology and experimental therapeutics.

[11]  T. Su,et al.  Delta Opioid Peptide Augments Functional Effects and Intrastriatal Graft Survival of Rat Fetal Ventral Mesencephalic Cells , 2001, Cell transplantation.

[12]  G. Haddad,et al.  δ-, but not μ- and κ-, opioid receptor activation protects neocortical neurons from glutamate-induced excitotoxic injury , 2000, Brain Research.

[13]  L. Opie,et al.  Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. , 2000, Journal of the American College of Cardiology.

[14]  T. Su,et al.  Delta Opioid Peptide[D- Ala2,D-Leu5]Enkephalin Promotes Cell Survival , 2000, Journal of Biomedical Science.

[15]  L. Opie,et al.  Opposing effects on infarction of delta and kappa opioid receptor activation in the isolated rat heart: implications for ischemic preconditioning , 2000, Basic Research in Cardiology.

[16]  G. Gross,et al.  Direct preconditioning of cardiac myocytes via opioid receptors and KATP channels. , 1999, Circulation research.

[17]  P. Menasché,et al.  Opening of potassium channels: the common cardioprotective link between preconditioning and natural hibernation? , 1999, Circulation.

[18]  P. Molina,et al.  Opiate modulation of hemodynamic, hormonal, and cytokine responses to hemorrhage. , 1999, Shock.

[19]  A. Hsu,et al.  Ischemic Preconditioning in the Intact Rat Heart Is Mediated by δ1- But Not μ- or κ-Opioid Receptors , 1998 .

[20]  D. S. Bruce,et al.  Isolation and partial characterization of an opioid-like 88 kDa hibernation-related protein. , 1998, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.

[21]  A. Hsu,et al.  TAN-67, a δ1-opioid receptor agonist, reduces infarct size via activation of Gi/o proteins and KATP channels. , 1998, American journal of physiology. Heart and circulatory physiology.

[22]  L. Janský,et al.  Hibernation triggers and cryogens: do they play a role in hibernation? , 1997, Comparative biochemistry and physiology. Part A, Physiology.

[23]  S. Bolling,et al.  Use of "natural" hibernation induction triggers for myocardial protection. , 1997, The Annals of thoracic surgery.

[24]  S. Bolling,et al.  The use of hibernation induction triggers for cardiac transplant preservation. , 1997, Transplantation.

[25]  S. Bolling,et al.  Extended lung preservation with the use of hibernation trigger factors. , 1996, The Annals of thoracic surgery.

[26]  T. Su,et al.  Extension of tissue survival time in multiorgan block preparation with a delta opioid DADLE ([D-Ala2, D-Leu5]-enkephalin) , 1994, The Journal of thoracic and cardiovascular surgery.

[27]  J. Ludbrook,et al.  The decompensatory phase of acute hypovolaemia in rabbits involves a central δ1-opioid receptor , 1994 .

[28]  P. Safar,et al.  A simple survival model of volume-controlled hemorrhagic shock in awake rats. , 1991, Resuscitation.

[29]  P. Safar,et al.  Dying pattern in volume-controlled hemorrhagic shock in awake rats. , 1991, Resuscitation.

[30]  G. Haddad,et al.  Effect of enkephalins on cardiac output and regional blood flow in conscious dogs. , 1989, The American journal of physiology.

[31]  J. Ojewole,et al.  Uses of pharmaco-EEG and pharmacokinetic-pharmacodynamic modeling in the clinical scenario. , 2002 .

[32]  T. Su,et al.  NEUROPHARMACOLOGY: Treatment with delta opioid peptide enhances in vitro and in vivo survival of rat dopaminergic neurons , 2000 .

[33]  S. Schultz,et al.  A century of (epithelial) transport physiology: from vitalism to molecular cloning. , 1998, The American journal of physiology.

[34]  T. Su,et al.  delta Opioid extends hypothermic preservation time of the lung. , 1996, The Journal of thoracic and cardiovascular surgery.

[35]  T. Su,et al.  Further studies on opioids and hibernation: delta opioid receptor ligand selectively induced hibernation in summer-active ground squirrels. , 1988, Life sciences.